Videos

Aaron Gerds, MD, MS, explains the factors to consider when selecting an appropriate JAK inhibitor for patients with myelofibrosis.

When switching JAK inhibitors for myelofibrosis, Aaron Gerds, MD, MS, advises stopping ruxolitinib and starting the new JAK inhibitor the next day due to its short half-life, though tapering ruxolitinib over 1 week is recommended for patients on higher doses to avoid rebound symptoms; pacritinib and fedratinib have longer half-lives so a 1-week washout can be considered.

Aaron Gerds, MD, MS, explains that myelofibrosis patients on JAK inhibitors need regular monitoring of blood counts, liver enzymes, and cardiac events to check for reactivation.

Aaron Gerds, MD, MS, details the use of momelotinib in myelofibrosis treatment.

Aaron Gerds, MD, MS, outlines how first-line treatment choice for myelofibrosis depends on symptoms, spleen size, and blood counts, while second-line choice depends on prior side effects and medical history.

Yazan Madanat, MD, comments on the updates that were recently presented at ASH 2023 for the management of lower-risk MDS and discusses the impact of emerging therapies.

David Zhen, MD, provides advice to oncologists treating patients with upper gastric cancer and offers closing thoughts on the future treatment landscape, highlighting challenges and unmet needs.

Turning the focus to ongoing research, an expert on upper gastric cancer discusses novel targets being investigated in clinical trials and the evolving treatment landscape.

A medical oncologist discusses the treatment of patients with gastric adenocarcinoma who have progressed following treatment with immunotherapy.

Explanation of how these data apply to community oncologists.

Presenting real-world data on the efficacy and safety of teclistamab for R/R MM.

David Zhen, MD, provides clinical insights on the management of adverse events stemming from immunotherapy in patients with upper gastric cancer.

Expert perspectives on the role of immunotherapies in upper gastrointestinal cancers, highlighting the CheckMate 649 study investigating frontline nivolumab plus chemotherapy.

Discussion of the real-world effectiveness of teclistamab in R/R MM and the impact on treatment guidelines and practice.

Danai Dima, MD, further explores the patient characteristics in the R/R MM teclistamab real-world study.

A medical oncologist reviews the available frontline treatment options for patients with gastric adenocarcinoma.

David Zhen, MD, reviews the profile of a 60-year-old man with stage IV gastric adenocarcinoma and offers his initial impressions on the case.

A description and overview of teclistamab and its mechanism of action.

Expert insights into the evolving therapeutic landscape for newly diagnosed multiple myeloma, highlighting transplant eligibility, combination regimens, and emerging data.

Igor Astsaturov, MD, PhD, discusses the planned phase 1 trial of LP-184 in multiple advanced solid tumors and central nervous system cancers, including pancreatic cancer.

Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in leukemia and lymphoma.

Medical oncologists discuss recent data from the POLARIX study investigating polatuzumab vedotin plus R-CHP in patients with diffuse large B-cell lymphoma.

Mazyar Shadman, MD, MPH, and the Oncology Brothers discuss recent data from SWOG S1826 on nivolumab-AVD in patients aged 60 years and older with advanced stage Hodgkin lymphoma.

Experts on leukemia review the biomarker subgroup analysis from the SEQUOIA study looking at zanubrutinib in patients with treatment-naïve CLL/SLL without 17p deletion.

Following ASH 2023, Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent data from the ALPINE study investigating zanubrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Shannon Westin, MD, MPH, FACOG, discusses her hopes following the presentation of promising data from the phase 3 DUO-E trial of durvalumab plus chemotherapy followed by durvalumab and olaparib maintenance in patients with newly diagnosed advanced or recurrent endometrial cancer.

Patrick Forde, MBBCh offers an overview of current standard-of-care treatments as well as emerging immunotherapy options for treating early-stage, resectable non-small cell lung cancer.

Aaron Gerds, MD, MS, explains that unlike solid tumors, blood cancers are systemic, so risk stratification models like DIPSS that use readily available data on blood counts and physical exam are more useful prognostically; however, mutation analysis is becoming increasingly important for determining prognosis and targeting therapies.

Aaron Gerds, MD, MS, presents the case of a 73-year-old man with myelofibrosis.

Dipti Patel-Donnelly, MD, discusses the gaps between academic centers and community oncology regarding treatments for hematologic malignancies.